KRAS and lung adenocarcinoma: We thus demonstrate the prognostic value of RAG classification and RI quantification in 500+ lung adenocarcinoma patients from two independent cohorts, benchmarked against the failure of KRAS mutational status or previous RAS signatures to predict patient outcomes.